Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZBIO
Strong SellHot AirZenas BioPharma, Inc. · Healthcare · United States · $2.0B · Avg Vol: $21M/d
COMPANY DESCRIPTION
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immunology- and inflammation-focused therapies. The company's competitive moat is centered on its proprietary pipeline of bifunctional antibodies, led by its candidate obexelimab, which targets autoimmune diseases through a novel mechanism of action. It operates as an early-stage biotechnology innovator aiming to address significant unmet medical needs in global immunology markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 50.0M | 5.0M | 10.0M | -55.3% | 1.0M | 12.3M | 63.7M | 152.5% |
| EPS | -9.26 | -2.13 | -11.89 | -8.44 | — | -9.63 | -5.62 | -4.66 | — |
| Shares | 39.8M | 39.8M | 41.8M | 54.5M | +36.9% | 65.2M | — | — | — |
| Debt | 1.5M | 21.1M | 1.0M | 1.3M | -4.6% | — | — | — | — |
| Equity | -192.3M | -225.7M | 312.5M | 242.1M | -22.5% | — | — | — | — |
| Op CF | -65.7M | -30.5M | -119.7M | -172.3M | — | -226.0M | — | — | — |
| Inv CF | -2.2M | -17.0K | -30.6M | -251.9M | — | — | — | — | — |
| Fin CF | 59.4M | 20.1M | 413.0M | 215.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZBIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc.(you) | $2.0B | 15 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.9B | 14 | Strong Sell |
| PVLA | Palvella Therapeutics, Inc. | $2.2B | 16 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 13 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 12 | Strong Sell |
| BRVE | Braveheart Bio, Inc. | $1.9B | 11 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%